NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

BlossomHill Therapeutics, Inc. (BLSM) Stock Analysis

BlossomHill Therapeutics, Inc. (BLSM) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

BLSM

$15.60

+$1.20 (+8.33%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BLSM with… →

BLSM Key Statistics

As of Oct 21, 2026
Trading
Open
$14.94
Previous Close
$14.40
Day's Range
14.51–15.64
52-Week Range
14.70–27.99
Volume
76.22K
Valuation
Market Cap
$476.14M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.65
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$60.56M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
31.78M
Dividend and dates
Earnings Date
November 16, 2026estimated
Avg Volume
250.12K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

BlossomHill Therapeutics, Inc. (BLSM) has a market capitalization of $476.14M.

In fiscal 2025, BLSM reported revenue of $0.00.

BLSM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$60.56M—
2024$0.00−$30.70M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$64.02M−$60.56M—
2024$0.00—−$36.40M−$30.70M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 19 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values BlossomHill Therapeutics, Inc. (BLSM) at $476.14M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 69 employees.

The most recent close on file for BLSM is $15.60, dated October 21, 2026. That is +$1.20 (+8.33%) against the previous close. The 52-week range on file runs from $14.70 to $27.99. The latest close sits 6.12% above that 52-week low.

Financial Health

In fiscal 2025, BlossomHill Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $60.56M. Trailing earnings per share are −4.65.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Growth & Income

No dividend is on file for BLSM.

So far in 2026 the total return is −2.50%.

Peer Comparison

BlossomHill Therapeutics, Inc. (BLSM) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
BlossomHill Therapeutics, Inc. BLSM $476.14M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. BlossomHill Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About BlossomHill Therapeutics, Inc.

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.

Visit website →